ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 988,40
0,39%
Dow Jones
38 789,64
0,29%
DAX
18 120,13
0,70%
Brent Oil
83,40
0,33%
Bitcoin
63 805,00
-0,30%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Ocugen Inc (OCGN)

  7. Ocugen Inc (OCGN) Actualités

OCGN Ocugen Inc

1,42
0,09 (6,77%)
Dernière mise à jour : 15:40:43
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Ocugen Inc OCGN NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,09 6,77% 1,42 15:40:43
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,34 1,33 1,43 1,33
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
03/5/202413:30GLOBEOcugen to Host Conference Call on Tuesday, May 14 at 8:30..
02/5/202413:15GLOBEOcugen Announces CSO to Present on Modifier Gene Therapy at..
29/4/202412:45GLOBEOcugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data..
26/4/202415:05GLOBEUPDATE -- Ocugen to Present on Modifier Gene Therapy..
26/4/202412:30GLOBEOcugen to Present on Modifier Gene Therapy Platform at..
19/4/202413:13GLOBEOcugen Announces Dosing Completion of Subjects with..
12/4/202413:30GLOBEOcugen to Participate in Fireside Chat at the Emerging..
10/4/202413:02GLOBEOcugen, Inc. Announces Positive Scientific Advice from the..
08/4/202412:30GLOBEOcugen, Inc. Announces U.S. FDA Clearance of IND Amendment..
05/4/202413:02GLOBEOcugen Announces Positive Data and Safety Monitoring Board..
02/4/202414:00GLOBEOcugen Provides Business Update with Certain Financials for..
02/4/202400:08GLOBEOcugen Announces Positive Data and Safety Monitoring Board..
01/4/202423:43GLOBEOcugen to Host Conference Call on Tuesday, April 2 at 8:30..
18/3/202411:30GLOBEOcugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical..
13/3/202413:00GLOBEOcugen, Inc. Announces Dosing Completion of Subjects with..
06/3/202413:30GLOBEOcugen to Present at Investing in Cures Summit
28/2/202414:00GLOBEOcugen Clinical Showcase Webcast Now Available
26/2/202414:30GLOBEOcugen Chairman and CEO to present at Abu Dhabi Family..
22/2/202422:05GLOBEOcugen, Inc. Announces Dosing Completion of Subjects with..
21/2/202422:05GLOBEOcugen to Present at 2024 BIO CEO & Investor Conference
21/2/202417:22EDGAR2Form 8-K - Current report
14/2/202413:30GLOBEOcugen to Host Clinical Showcase in New York City..
31/1/202414:00GLOBEOcugen to Present at Pharma Market Research Conference
16/1/202413:30GLOBEOcugen, Inc. Announces Bob Smith Joins Business Advisory..
08/1/202412:05EDGAR2Form 8-K - Current report
05/1/202422:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202423:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202423:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202321:09EDGAR2Form 8-K - Current report
21/12/202312:30GLOBEOcugen Gains FDA Alignment on Key Aspects of OCU400—Modifier..
19/12/202313:30GLOBEOcugen Announces OCU400 Receives Regenerative Medicine..
13/12/202313:30GLOBEOcugen, Inc. Announces First Patient Dosed in Phase 1/2..
29/11/202313:30GLOBEOcugen CEO to Present at NobleCon19 – Noble Capital Markets’..
10/11/202313:30GLOBEOcugen, Inc. Announces First Patient Dosed in Phase 1/2..
09/11/202314:02EDGAR2Form 8-K - Current report
09/11/202313:02EDGAR2Form 8-K - Current report
09/11/202312:30GLOBEOcugen Provides Business Update with Third Quarter 2023..
09/11/202312:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202313:45GLOBEOcugen CSO to Participate in 4th Annual Dry AMD Therapeutic..
02/11/202312:30GLOBEOcugen to Host Conference Call on Thursday, November 9 at..
10/10/202315:05EDGAR2Form 8-K - Current report
10/10/202312:30GLOBEOcugen Mucosal Vaccine Candidate OCU500 Selected by..
04/10/202313:00GLOBEOcugen to Present at the 2023 Cell & Gene Meeting on the..
29/9/202313:30GLOBEOcugen CSO to Participate in 4th Annual Gene Therapy for..
28/9/202301:30GLOBEOcugen to Participate in Fireside Chat at Chardan’s 7th..
21/9/202313:30GLOBEOcugen, Inc. Announces Connie Collingsworth Joins Business..
20/9/202314:00GLOBEOcugen to Participate in Panel at Cantor Fitzgerald Global..
19/9/202322:54EDGAR2Form 8-K - Current report
19/9/202322:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Dernières Valeurs Consultées

NASDAQ
OCGN
Ocugen
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés